Capital Royalty Group is a global healthcare investor that has operated across the globe since 2003.
Investing capital debt and equity structures in collaborative partnerships to focus on minimized dilution and strong value-added support for companies has been a consistent role for Capital Royalty Group. The firm is interested in companies such as Harmony Biosciences, HNI Healthcare, Earlens Corporation, EndoGastric Solutions, Synergy Pharmaceuticals, Stonebridge Biopharma, and Silk Road Medical.
T2 Biosystems is a Lexington, Massachusetts-based company developing diagnostic products targeting sepsis and in vitro diagnostic products intended to target sepsis, hemostasis, bacteria, and lyme disease founded in 2006 by Robin Toft.
A biotechnology company developing diagnostic tools for cancer
Biodesix is a company focused on molecular diagnostics and related products.
EndoGastric Solutions is a medical device company developing and commercializing innovative, evidence-based, incisionless surgical technology for the treatment of gastroesophageal reflux disease (GERD).
Blue Belt Technologies is a medical device company.
Silk Road Medical is a Sunnyvale, California-based healthcare company.